

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: January 30, 2020 Administrative Circular: 2020:01

ATTN: Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 2 – Immunization of Special Populations

Part 2 – Immunization of Special Populations

Specific Immunocompromising Conditions

Hematopoietic Stem Cell Transplantation (HSCT)

- Content added indicating that pre-vaccination serology is no longer recommended for HSCT recipients prior to vaccination. If an individual has been tested prior to vaccination and has evidence of immunity for a respective disease, they should be vaccinated regardless of these results. This is due to the decline in antibody levels 1-4 years after HSCT if the recipient is not re-immunized.
- Content added indicating that patients receiving B-cell depleting agents (e.g. rituximab) should wait until 6 months after their last dose prior to vaccine initiation.
- Content added indicating that live vaccines should not be administered until 24 months
 post-HSCT and then only if there is no ongoing anticancer therapy, immunosuppression,
 IVIg or subcutaneous Ig, or active graft-versus-host disease (GVHD). Active GVHD has
 been specified to differentiate from sequelae of GVHD in the eyes and mouth which is
 not active but the symptoms can persist for life. Such individuals may no longer be
 receiving immunosuppressive therapy and may receive live vaccines.
- Table 1 footnotes have been revised as follows:
 - Footnote I: A link to Part 4 Biological Products, Gardasil®9 has been added for information on eligibility indications.
 - Footnote J:
 - Content related to the receipt of live vaccines has been revised as above.
 - Serological testing is no longer recommended after the first dose of MMR vaccine. Provide 2 doses of MMR vaccine separated by 2 months and measure measles and rubella IgG 1 month after the 2nd dose.
 - Footnote L:
 - Content related to the receipt of live vaccines has been revised as above.





BC Centre for Disease Control Provincial Health Services Authority

- Serological testing is no longer recommended prior to the first dose of varicella vaccine. Provide 2 doses of varicella vaccine separated by 2 months, and measure varicella IgG 1 month after the 2nd dose.
- Table 2 footnotes have been revised as follows:
 - Footnote I: Content related to the receipt of live vaccines has been revised as above.
 - Footnote J: Serological testing is no longer recommended after the first dose of MMR vaccine. Provide 2 doses of MMR vaccine separated by 2 months and measure measles and rubella IgG 1 month after the 2nd dose.
 - Footnote K: Serological testing is no longer recommended prior to the first dose of varicella vaccine. Provide 2 doses separated by 3 months, and measure varicella IgG 1 month after the 2nd dose.

Please remove page numbers: 1-6 dated October 2019 Please add new page numbers: 1-7 dated January 2020

If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM Medical Director

Communicable Diseases & Immunization Service

BC Centre for Disease Control

pc:

Provincial Health Officer Dr. Bonnie Henry

Dr. David Patrick
Interim Executive Lead
BC Centre for Disease Control

BC Ministry of Health, Population & Public Health Division:

Craig Thompson Director, Immunization

Kim Bruce Acting Executive Director, Public Health Services

Page 2 of 2



